Showing results (71-80 of 209) with videos related to
Sort By:
Pageof 21
Alimentary Pharmacology & Therapeutics|December 6, 2017
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitisS Singh, M Fumery, W J Sandborn, et al.Mayo Clinic Proceedings|February 1, 1997
Duodenal obstruction: diagnosis by gastroduodenal manometryE V Loftus, G Farrugia, J H Donohue, et al.Inflammatory Bowel Diseases|March 16, 2012
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experienceS V Kane, S Horst, W J Sandborn, et al.Diseases of the Colon and Rectum|August 1, 1997
Lymphoma of the pouch after ileal pouch-anal anastomosis: report of a caseD C Nyam, J H Pemberton, W J Sandborn, et al.Journal of Pediatric Gastroenterology and Nutrition|August 1, 1992
Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitisW J Sandborn, D H Goldman, G M Lawson, et al.Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.Alimentary Pharmacology & Therapeutics|June 6, 2003
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trialW J Sandborn, B E Sands, D C Wolf, et al.Alimentary Pharmacology & Therapeutics|June 17, 2015
Systematic review: colitis associated with anti-CTLA-4 therapyA Gupta, K M De Felice, E V Loftus, et al.Alimentary Pharmacology & Therapeutics|March 14, 2013
Meta-analysis: serological markers and the risk of acute and chronic pouchitisS Singh, P K Sharma, E V Loftus, et al.Alimentary Pharmacology & Therapeutics|May 1, 2001
Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjectsB Coulie, M Camilleri, A E Bharucha, et al.Pageof 21